Agilent Technologies Inc. has announced a new strategic partnership with National University of Singapore (NUS), acting through the Yong Loo Lin School of Medicine (NUS Medicine), to establish the NUS-Agilent Centre of Excellence (CoE) in cell metabolism, a scientific collaboration to advance cardiovascular and metabolic disease translational research over the next four years.

As part of the collaboration, Agilent is providing its game-changing xCELLigence, Seahorse XF and BioTek technologies to support targeted and untargeted metabolic profiling for large-scale population-based cohorts across translational research. The CoE is part of Project RESET, a five-year government-funded research initiative focused on developing new early detection methods for cardiovascular diseases and elevating Singapore's global prominence in precision medicine.

The integrated use of Agilent's metabolic and cellular phenotyping platforms will provide a world-class multimodal workflow solution to study cells at unrivalled speed and scale. The NUS-Agilent CoE also supports the Cardiovascular Metabolic Disease Translational Research Programme (CVMD-TRP) and Preclinical Platform for Development of Therapeutics for Heart Failure (PREVENT-HF) at NUS Medicine to accelerate the discovery of novel insights into the complex mechanisms of heart disease.   

Image caption- (from left) Dr Vimala Sreenivasan, Regional Associate Vice President of Sales at Agilent; Chow Woai Sheng, Singapore General Manager and Vice President of Global Instrument Manufacturing at Agilent; Professor Roger Foo, Zayed Bin Sultan Al Nahyan Professor in Medicine, Corresponding Principal Investigator of Project RESET, Vice-Dean (Research) and Director of the Cardiovascular Metabolic Disease Translational Research Programme at NUS Medicine; and Associate Professor Choi Hyung Won, Principal Investigator, Cardiovascular-Metabolic Disease Translational Research Programme at NUS Medicine.